Dendrimer nanotechnology for enhanced formulation and controlled delivery of resveratrol

Annals of the New York Academy of Sciences

Volumn 1348, Issue 1, 2015, Pages 134-140

  Chauhan, Abhay S ^a  

^a Department of Pharmaceutical Sciences   (United States)

Author keywords

bioavailability; dendrimer; PAMAM; resveratrol; solubility; stability

Indexed keywords

DENDRIMER; NANOMATERIAL; POLYAMIDOAMINE; RESVERATROL;

AQUEOUS SOLUTION; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HUMAN; METABOLIC STABILITY; NANOENGINEERING; NANOTECHNOLOGY; PH;

EID: 85006371505     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12816     Document Type: Article

References (41)

1. Svenson, S., Ed. 2004. Carrier-Based Drug Delivery. ACS Symposium Series. Vol. 879. Washington DC: American Chemical Society.
2. Svenson, S., Ed. 2006. Polymeric Drug Delivery I: Particulate Drug Carriers, ACS Symposium Series. Washington DC: American Chemical Society.
3. Kulharia, H., D. Pooja, S.K. Prajapatia & A.S. Chauhan. 2010. Performance evaluation of PAMAM dendrimer based Simvastatin formulations. Int. J. Pharm. 405: 203–209.
4. Chauhan, A.S., N.K. Jain & P.V. Diwan. 2010. Pre-clinical and behavioural toxicity profile of PAMAM dendrimer in mice Proc. R. Soc. A. 466: 1535–1550.
5. Chauhan, A.S., P.V. Diwan, N.K. Jain & D.A. Tomalia. 2009. Simple, terminal functionalized poly(amidoamine) (PAMAM) dendrimers: in vivo active macromolecular anti-inflammatory agents. Biomacromolecule 5: 1195–1202.
6. Svenson, S. & A.S. Chauhan. 2008. Dendrimers for enhanced drug solubilization. Nanomedicine 3: 679–702.
7. Chauhan, A.S., S. Svenson, L. Reyna & D.A. Tomalia. 2007. Solubility enhancement propensity of PAMAM nanoconstructs. Mater. Matt.—Nanomater. Issue 2: 24–26.
8. Asthana, A., A.S. Chauhan, P.V. Diwan & N.K. Jain. 2005. Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS PharmSci. Tech. 6: E536–542.
9. Chauhan, A.S., N.K. Jain & P.V. Diwan. 2004. Solubility enhancement of indomethacin using dendrimer complex and bio-disposition profile of these complexes in arthritic rats. J. Drug Targeting 12: 575–583.
10. Chauhan, A.S., S. Sridevi, K.B. Chalasani, et al. 2003. Dendrimer mediated transdermal delivery: enhanced bioavailability of indomethacin. J. Control. Release 90: 335–343.
11. Svenson, S. 2007. “Dendrimers.” In Kirk–Othmer Encyclopedia of Chemical Technology. 5th ed. Vol. 26: 786–812.
12. Svenson, S. & D.A. Tomalia. 2005. Dendrimers in biomedical applications—reflections on the field. Adv. Drug Deliv. Rev. 57: 2106–2129.
13. Svenson, S & D.A. Tomalia. 2006. “Dendrimers as nanoparticulate drug carriers.” In Nanoparticulates as Drug Carriers. V.P. Torchilin, Ed.: 277–299. London, UK: Imperial College Press.
14. Gillies, E.R. & J.M.J. Fréchet. 2005. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 10: 35–42.
15. Tomalia, D.A. 2005. Birth of a new macromolecular architecture—dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog. Polym. Sci. 30: 294–324.
16. Gupta, U., H.B. Agashe, A. Asthana & N.K. Jain. 2006. Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. Biomacromolecules 7: 649–658.
17. Kannan, R.M., E. Nance, S. Kannan & D.A. Tomalia. 2014. Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications. J. Intern. Med. 276: 579–617.
18. Menjoge, A.R., R.M. Kannan & D.A. Tomalia. 2010. Drug Discov. Today 15: 171–185.
19. Tomalia, D.A., J.B. Christensen & U. Boas. 2012. Dendrimers, Dendrons and Dendritic Polymers: Discovery, Applications, the Future. New York: Cambridge University Press.
20. Cheng, Y., Z. Xu, M. Ma & T. Xu. 2008. Dendrimers as drug carriers: applications in different routes of drug administration. J. Pharm. Sci. 97: 123–143.
21. Baur, J.A. & D.A. Sinclair. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug. Discov. 5: 493–506.
22. Baur, J.A., K.J. Pearson, N.L. Price & H.A. Jamieson. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337–342.
23. Jang, M., L. Cai, G.O. Udeani, et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218–220.
24. ClinicalTrial.gov. A service of the U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/results?term=resveratrol&Search=Search. Accessed on Feb 19, 2015.
25. Delmas, D., A. Lancon, D. Colin, et al. 2006. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr. Drug Targets 7: 423–442.
26. Goldberg, D.M., J. Yan & G.J. Soleas. 2003. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36: 79–87.
27. Walle, T., F. Hsieh, M.H. DeLegge, et al. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32: 1377–1382.
28. Boocock, D.J., G.E. Faust, K.R. Patel, et al. 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16: 1246–1252.
29. Starpharma. http://www.starpharma.com/dendrimers.asp. Accessed August 2, 2007.
30. Chauhan, A.S., P.V. Diwan, N.K. Jain & K.V. Ragahvan. 2003. Macromolecular compounds as potential anti-inflamma-tory agents. PCT patent. WO 03/080121.
31. Shaunak, S., S. Thomas, E. Gianasi, et al. 2004. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat. Biotechnol. 22: 977–984.
32. Luo, D., K. Haverstick, N. Belcheva, et al. 2002. Poly(ethylene glycol)-Conjugated PAMAM Dendrimer for Biocompatible, High-Efficiency DNA Delivery. Macromolecules 35: 3456–3462.
33. Cited May 20, 2015. http://nano.med.umich.edu/publications/Majoros-2006-Biomacro.pdf.
34. Tomalia, D.A. & J.M.J. Frechet. 2002. Discovery of dendrimers and dendritic polymers: A brief historical perspective. J. Polym. Sci. Part A: Polym. Chem. 40: 2719.
35. Chauhan, A.S., N.K. Jain & P.V. Diwan. 2010. Pre-clinical and behavioural toxicity profile of PAMAM dendrimers in mice. Proc. Royal Soc. A: Math. Phys. Eng. Sci. 466: 1535–1550.
36. Cited May 20, 2015. http://ncl.cancer.gov/120406.pdf.
37. Kaminskas, L M., B J. Boyd & C J. Porter. 2011. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine (Lond.) 6: 1063–1084.
38. Kulhari, H., D.P. Kulhari, S.K. Prajapati & A.S. Chauhan. 2013. Optimization of carboxylate-terminated PAMAM dendrimer-mediated cisplatin formulation. Drug Develop. Ind. Pharm. 41: 232–238.
39. Kulhari, H., D.P. Kulhari, M.K. Singh & A.S. Chauhan. 2013. Pharmacokinetic and pharmacodynamic studies of poly(amidoamine) dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia. Mol. Pharm. 10: 2528–2533.
40. Chauhan, A.S., E.A. Newenhouse & A.H. Gerhardt. 2015. Dendrimer–Resveratrol Complex. Patent WO/2015/027068A1.
41. Red wine and resveratrol: Good for your heart? http://www.mayoclinic.org/diseasesconditions/heart-disease/in-depth/red-wine/art-20048281. Accessed May 20, 2015.